The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study
Por:
Mocroft, A, Miro, JM, Wandeler, G, Llibre, JM, Boyd, A, van Bremen, K, Beniowski, M, Mikhalik, J, Cavassini, M, Maltez, F, Duvivier, C, Foppa, CU, Knysz, B, Bakowska, E, Kuzovatova, E, Domingo, P, Zagalo, A, Viard, JP, Degen, O, Milinkovic, A, Benfield, T, Peters, L
Publicada:
1 jul 2022
Ahead of Print:
1 dic 2021
Resumen:
Objectives The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods All persons aged >= 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer. Conclusions We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
Filiaciones:
Mocroft, A:
Rigshosp, CHIP, Copenhagen, Denmark
UCL, Inst Global Hlth, Ctr Clin Res Epidemiol Modelling & Evaluat CREME, London, England
Miro, JM:
Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Spain
Wandeler, G:
Univ Bern, Univ Hosp Bern, Dept Infect Dis, Bern, Switzerland
Llibre, JM:
Hosp Germans Trias Pujol, Infect Dis Unit Fight AIDS Fdn, Badalona, Spain
Boyd, A:
Stichting HIV Monitoring SHM, Amsterdam, Netherlands
Publ Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands
van Bremen, K:
Univ Hosp Bonn, Dept Med, Bonn, Germany
Beniowski, M:
Specialist Hosp, Diagnost & Therapy AIDS, Chorzow, Poland
Mikhalik, J:
Crimean Republican AIDS Ctr, Simferopol, Ukraine
Cavassini, M:
Univ Lausanne, Serv Infect Dis, Lausanne, Switzerland
Lausanne Univ Hosp, Serv Infect Dis, Lausanne, Switzerland
Maltez, F:
Curry Cabral Hosp, Lisbon, Portugal
Duvivier, C:
Hop Necker Enfants Malad, AP HP, Necker Pasteur Infectiol Ctr, Dept Infect Dis, Paris, France
Univ Paris, INSERM, U1016, Paris, France
HU Imagine, Paris, France
Inst Pasteur Med Ctr, Inst Pasteur, Paris, France
Foppa, CU:
Ist Sci San Raffaele, Infect Dis, Milan, Italy
Knysz, B:
Wroclaw Med Univ, Wroclaw, Poland
Bakowska, E:
Hosp Infect Dis Warsaw, Warsaw, Poland
Kuzovatova, E:
Academicia IN Blokhina Nizhny Novgorod Sci Res In, Nizhnii Novgorod, Russia
Domingo, P:
Hosp Holy Cross & St Paul, Dept Infect Dis, Barcelona, Spain
Zagalo, A:
Santa Maria Univ Hosp, Dept Infect Dis, Lisbon, Portugal
Viard, JP:
AP HP, Diagnost & Therapeut Ctr, Hotel Dieu, Paris, France
Degen, O:
Univ Clin Hamburg Eppendorf, Hamburg, Germany
Milinkovic, A:
Chelsea & Westminster Hosp, London, England
Benfield, T:
Univ Copenhagen, Dept Infect Dis, Hosp Amager & Hvidovre, Hvidovre, Denmark
Peters, L:
Rigshosp, CHIP, Copenhagen, Denmark
Open Access
|